Description
Thermal pulsation is a treatment option for meibomian gland dysfunction. Meibomian gland dysfunction is recognized as the major cause of dry eye syndrome. Thermal pulsation applies heat to the palpebral surfaces of the upper and lower eyelids directly over the meibomian glands, while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands.

Background
Dry Eye Syndrome 
Dry eye syndrome (DES), dry eye disease, or dysfunctional tear syndrome, either alone or in combination with other conditions, is a frequent cause of ocular irritation that leads patients to seek ophthalmologic care. DES is considered a significant public health problem. It is estimated to affect between 14% and 33% of the population worldwide.^1,2 The prevalence of DES increases with age, especially in postmenopausal women. It is estimated that DES affects more than 7 million Americans older than 40 years of age,¹ and approximately 1 to 4.3 million Americans between 65 and 84 years of age.³ Prevention and treatment of DES are expected to be of greater importance as the population ages.

Treatment
Current treatment options for meibomian gland dysfunction include physical expression to relieve the obstruction, administration of heat (warm compresses) to the eyelids to liquefy solidified meibomian gland contents, eyelid scrubs to relieve external meibomian gland orifice blockage, and medications (e.g., antibiotics, topical corticosteroids) to mitigate infection and inflammation of the eyelids.^4,5 These treatment options, however, have shown limited clinical efficacy. For example, physical expression can be very painful given the amount of force needed to express obstructed glands. Warm compress therapy can be time-consuming and labor intensive, and there is limited evidence that medications relieve MGD.⁵ While the symptoms of DES often improve with treatment, the disease usually is not curable and may lead to substantial patient and physician frustration. Dry eyes can be a cause of visual morbidity and may compromise results of corneal, cataract, and refractive surgery. Inadequate treatment of DES may result in increased ocular discomfort, blurred vision, reduced quality of life, and decreased productivity.

Regulatory Status

Eyelid thermal pulsation systems (FDA product code: ORZ) cleared by the U.S. Food and Drug Administration (FDA) are summarized in Table 1.

Table 1. Eyelid Thermal Pulsation Systems Cleared by the FDA

*Other 501(k) numbers are associated with more recent versions of the device.

Policy
Eyelid thermal pulsation therapy to treat dry eye syndrome is investigational and/ or unproven and therefore considered NOT MEDICALLY NECESSARY.

Policy Guidelines
Please see the Codes table for details.

Benefit Application
BlueCard^®/National Account Issues
State or federal mandates (e.g., FEP) may dictate that all U.S. Food and Drug Administration (FDA)-approved devices, drugs, or biologics may not be considered investigational, and thus these devices may be assessed only on the basis of their medical necessity.

Rationale  

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., people of color [African American, Asian, Black, Latino and Native American]; LGBTQIA [lesbian, gay, bisexual, transgender, queer, intersex, asexual]; women; and people with disabilities [physical and invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

Dry Eye Syndrome
Clinical Context and Therapy Purpose
The purpose of eyelid thermal pulsation in individuals who have dry eye syndrome is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

Populations
The relevant population(s) of interest is individuals with dry eye syndrome. Dry eye syndrome is often classified into the aqueous-deficient subtype or the evaporative subtype, although classification is not mutually exclusive. Dry eye syndrome is a multifactorial disease of the ocular surface that may require a combination approach to treatment. Meibomian gland dysfunction (MGD), characterized by changes in gland secretion with or without concomitant gland obstruction, is recognized as the most common cause of evaporative dry eye and may also play a role in aqueous-deficient dry eye.

Interventions
The therapy being considered is eyelid thermal pulsation. The LipiFlow Thermal Pulsation System is one of the devices developed to relieve MGD. This device heats the palpebral surfaces of both the upper and lower eyelids, while applying graded pulsatile pressure to the outer eyelid surfaces. The LipiFlow System is composed of a disposable ocular component and a handheld control system. Following application of a topical anesthetic, the heated inner portion of the LipiFlow eyecup is applied to the conjunctival surface of the upper and lower eyelids. The outer portion of the device covers the skin surface of the upper and lower eyelids. The device massages the eyelids with cyclical pressure from the base of the meibomian glands in the direction of the gland orifices, thereby expressing the glands during heating.

Comparators
The following practices are currently being used to treat dry eye syndrome: standard treatment with warm compresses and eyelid massage. Current treatment options for MGD include physical expression to relieve the obstruction, administration of heat (warm compresses) to the eyelids to liquefy solidified meibomian gland contents, eyelid scrubs to relieve external meibomian gland orifice blockage, and medications (e.g., antibiotics, topical corticosteroids) to mitigate infection and inflammation of the eyelids.

Outcomes
The general outcomes of interest are symptoms, morbid events, and functional outcomes.

Tear break-up time (TBUT) is measured in seconds. Practice parameters from the American Academy of Ophthalmology (2013) have indicated that a tear break-up time of <10 s is considered abnormal.⁶

The Ocular Surface Disease Index (OSDI) assesses the patient’s frequency and severity of dry eye symptoms in specific contexts during the week prior to the examination. The minimal clinically important difference for the OSDI ranges from 4.5 – 7.3 for mild or moderate disease. The overall OSDI score defines the ocular surface as normal (0 – 12 points) or as having mild (13 – 22 points), moderate (23 – 32 points), or severe (33 – 100 points) disease.⁷

The Standard Patient Evaluation for Eye Dryness (SPEED) questionnaire is a self-reported measure of the frequency and severity of dryness, grittiness, scratchiness, soreness, irritation, burning, watering, and eye fatigue. It was developed by TearScience and validated in a 2013 study funded by TearScience.⁸ In this validation study, the mean SPEED score of symptomatic subjects was 21.0 and the mean of asymptomatic subjects was 6.25.

Study Selection Criteria
Methodologically credible studies were selected using the following principles:

• To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
• In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
• To assess longer term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
• Studies with duplicative or overlapping populations were excluded.

Review of Evidence
Systematic Reviews
Tao et al. (2023) reported results of a systematic review that informed an 'Ophthalmic Technology Assessment' commissioned by the American Academy of Ophthalmology.⁹ The review was designed to assess the efficacy and safety of thermal pulsation in improving signs or symptoms of MGD and dry eye compared with no therapy or conventional (nonthermal pulsation) therapy such as warm compress or eyelid hygiene. The literature search was performed in March 2023. For each study, the quality of study methodology was rated according to the American Academy of Ophthalmology’s guidelines. 8 studies were rated as providing level I evidence (well-designed and well-conducted randomized controlled trials and systematic reviews) and 3 studies were rated as providing level II evidence (well-designed cohort studies and nonrandomized controlled cohort or follow-up trials). All included studies evaluated the LipiFlow device. The review did not include a meta-analysis. The authors stated that 9/11 of the studies reported greater efficacy with LipiFlow compared to standard warm compress therapy and eyelid hygiene. In general, improvements were detected in both subjective and objective metrics of MGD within 1 to 12 months of thermal pulsation treatment compared with nontreatment. The authors noted that durability beyond several months is uncertain.

The RCTs identified in the Tao (2023) systematic review are described below in Tables 2 through 5.

Randomized Controlled Trials
Ten RCTs of eyelid thermal pulsation (LipiFlow System) for the treatment of dry eye syndrome have been published.Characteristics of RCTs are shown in Table 2. Results of the RCTs are summarized in Table 3. Study limitations are briefly described in Tables 4 and 5. Select studies are described below. Several additional RCTs, including trials evaluating systems other than LipiFlow, have been conducted but not published, see Table 6.

In the multicenter RCT by Lane et al. (2012), controls crossed over to treatment after 2 weeks; therefore, only the 2-week follow-up is available (Table 2).¹⁰ Results at 2 weeks showed statistically significant improvements in the primary and secondary outcome measures. Trial limitations included the short-term follow-up (2 weeks) for the primary comparative outcomes, lack of masking, and lack of intention-to-treat analysis. In addition, the control intervention did not include massage along with the warm compress, which is a common treatment for MGD.

An RCT by Finis et al. (2014), which reported on outcomes prior to crossover at 3 months, found a significant effect of treatment compared with controls for the primary outcome measure (Ocular Surface Disease Index [OSDI] score), but not for any other outcome measures.¹¹ The clinical significance of the 11.6-point improvement in OSDI score is unclear because final OSDI scores at 3 months (34.6 for LipiFlow, 40.0 for control) would still be classified as severe dry eye disease.

In a 2-stage multicenter RCT, Blackie et al. (2016) evaluated treatment effects of the LipiFlow System for patients with MGD and dry eye symptoms.¹² The first stage involved the open-label evaluation of treatment effects over the short term. Trialists compared the single, in-office, LipiFlow treatment with conventional treatments consisting of warm compress and eyelid hygiene control therapy, conducted twice daily for 3 months. Significant treatment effects relative to controls were observed for OSDI scores and meibomian gland secretion score (higher scores reflect less dysfunction) (Table 2). The second stage involved an observational crossover study to evaluate the long-term effects (from 3 to 12 months) of a single session using the LipiFlow System or in combination with other conventional treatments when considered necessary. Sustained treatment effects for the single LipiFlow treatment compared with the combination treatment subgroups were observed over the long-term for OSDI scores, but not for meibomian gland secretion scores. Trial limitations included lack of masking and lack of massage combined with warm compression, the usual treatment approach. The clinical significance of the 17- to 22-point improvement in OSDI scores observed across treatment and controls may be relatively small because final OSDI scores indicated that patients in both groups improved from severe disease to mild disease (treatment) or moderate disease (controls). The lack of blinding might also have led to an overestimation of the treatment effect of LipiFlow.

Tauber reported a single-center RCT (2020) comparing the LipiFlow System to twice-daily administration of lifitegrast ophthalmic solution 5% in patients with inflammatory MGD (N = 50; 25 patients per group).¹³ The co-primary outcomes were change in eye discomfort and tear lipid layer thickness from baseline to day 42. Results demonstrated that changes in the eye discomfort scores were significantly greater in the group that received lifitegrast, while changes in lipid layer thickness did not reach statistical significance between groups (Table 2). Trial limitations included lack of masking, attrition in the lifitegrast group (3 patients discontinued therapy), and selection of patients that had both MGD and inflammation (results may have differed in populations with MGD without inflammation).

Table 2. Summary of Characteristics of Randomized Controlled Trials of LipiFlow

MGD: meibomian gland dysfunction; MGS: Meibomian gland secretion score (0 – 45); NR: not reported.

Table 3. Summary of Key Results of Randomized Controlled Trials of LipiFlow

MGS: meibomian gland secretion; NR: not reported; NS: not significant; PRVSQ: Patient-Reported Visual Symptom Questionnaire; OSDI: Ocular Surface Disease Index; SD: standard deviation; SPEED: Standard Patient Evaluation for Eye Dryness; TBUT: tear break-up time; VAS: visual analog scale.
^aThe Meibomian Gland Evaluator device was developed by TearScience to evaluate gland secretion through gland expression to determine if meibomian glands are blocked.
^bPractice parameters from the American Academy of Ophthalmology (2013) have indicated that a tear break-up time of < 10 s is considered abnormal.⁶ Note that Zhao et al. (2016) is reported in percent not seconds.
^cThe OSDI assesses the patient’s frequency and severity of dry eye symptoms in specific contexts during the week prior to the examination. The minimal clinically important difference for the OSDI ranges from 4.5 – 7.3 for mild or moderate disease. The overall OSDI score defines the ocular surface as normal (0 – 12 points) or as having mild (13 – 22 points), moderate (23 – 32 points), or severe (33 – 100 points) disease.^7
dThe SPEED questionnaire is a self-reported measure of the frequency and severity of dryness, grittiness, scratchiness, soreness, irritation, burning, watering, and eye fatigue within 3 months of examination. It was developed by TearScience and validated in a 2013 study funded by TearScience.8, In this validation study, the mean SPEED score of symptomatic subjects was 21.0 and the mean of asymptomatic subjects was 6.25.
^eEye discomfort was reported using a visual analog scale from 0 to 100 mm. Symptoms were reported on a scale of 0 to 3 (0, none/absent; 1, mild; 2, moderate; and 3, severe) and included burning, stinging, foreign body sensation, dryness, pain/soreness, and photophobia.¹³
f Tear lipid layer thickness was measured using the LipiView (Johnson & Johnson Vision/TearScience) device, which uses noise canceling technology to measure the submicron thickness of the lipid layer. Authors did not provide the unit of measure for this outcome.¹³

Table 4. Study Relevance Limitations of Randomized Controlled Trials of LipiFlow

MGD: meibomian gland disfunction.
The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment. 
^aPopulation key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use; 5. Enrolled study populations do not reflect relevant diversity; 6. Other.
^bIntervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest; 5. Other.
^cComparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.
^dOutcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported; 7. Other.
^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 5. Study Design and Conduct Limitations of Randomized Controlled Trials of LipiFlow

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.
^aAllocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias; 5. Other.
^bBlinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician; 4. Other.
^cSelective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication; 4: Other.
^dData Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials); 7. Other.
^ePower key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference; 4. Other.
^fStatistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated; 5. Other.

Nonrandomized Comparative Trials and Observational Studies
Nonrandomized trials have been conducted but do not provide longer follow-up or inclusion of populations or outcomes of interest beyond what is available from RCTs and will not be discussed further.

Four other studies have evaluated long-term outcomes for some trial subjects who had undergone LipiFlow treatment. The study by Greiner (2013)²⁰ evaluated 18 of 30 subjects from 1 site of the Lane trial (described above).¹⁰ Several outcomes remained significantly improved from baseline, but the improvements were of lower magnitude at 1 year than at 1 month. Finis et al. (2014) evaluated 26 patients at 6 months after LipiFlow treatment.²¹ Several outcome measures remained improved 6 months after treatment. Another study of 20 patients conducted by Greiner (2016) found that most outcomes remained significantly improved up to 3 years relative to baseline.²² Lastly, a retrospective cohort study by Hura et al. (2020) compared dry eye disease markers and meibomian gland imaging between patients who had undergone LipiFlow treatment (n = 30) versus those who declined LipiFlow treatment (n = 13).²³ At 1 year, visible meibomian gland structure, tear break-up time, corneal staining, and meibomian gland evaluation scores all showed sustained improvements in the treatment group over the control. On the other hand, Standard Patient Evaluation for Eye Dryness scores and tear osmolarity did not show a sustained improvement 1-year post-therapy.

Summary of Evidence
For individuals who have dry eye symptoms consistent with meibomian gland dysfunction (MGD) who receive eyelid thermal pulsation, the evidence includes 10 randomized controlled trials (RCTs), nonrandomized comparison studies, and longer term follow-up of patients from RCTs and observational studies. Relevant outcomes are symptoms, morbid events, and functional outcomes. The RCTs have evaluated only the LipiFlow system. Study populations have been predominately White or Asian. The duration of MGD and previous treatments for MGD were unclear in the study populations. The majority of the RCTs have reported greater efficacy with LipiFlow compared to standard warm compress therapy and eyelid hygiene and improvements were generally seen in both objective metrics of MGD and in patient-reported symptoms for up to 3 months. Limited longer-term follow-up is available. The method for collecting adverse events in the studies was unclear but no serious adverse events were reported in any studies. Several additional RCTs have been conducted but have not been published. Observational studies have shown sustained treatment effects for most outcomes up to 3 years. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in Supplemental Information if they were issued by, or jointly by, a U.S. professional society, an international society with U.S. representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Ophthalmology
In 2018, the American Academy of Ophthalmology updated preferred practice patterns guidelines on dry eye syndrome.⁶ These guidelines list "In-office, physical heating and expression of the meibomian glands (including device-assisted therapies, such as LipiFlow, or intense pulse light treatment)" as 1 of several step-up treatments for patients who do not respond to conventional management, including the elimination of environmental factors and offending medications, dietary modifications, ocular lubricants, and lid hygiene and warm compresses.

In 2018, the American Academy of Ophthalmology updated preferred practice patterns guidelines on blepharitis.³ These guidelines cover the 3 clinical subcategories of blepharitis: staphylococcal, seborrheic, and meibomian gland dysfunction (posterior blepharitis specifically affects the meibomian glands). The following statements are made relevant to thermal pulsation treatment:

"There are also several in-office procedural treatments available that may theoretically unclog the inspissated meibomian gland orifices using intense pulsed light (IPL) or mechanical means (e.g., microblepharoexfoliation of the eyelid margin, meibomian gland probing, and/or devices using thermal pulsation). Although there have been industry-sponsored studies, independent, randomized, masked clinical trials have yet to be performed to assess efficacy of these costly, primarily fee-for-service treatments."

U.S. Preventive Services Task Force Recommendations
Not applicable

Ongoing and Unpublished Clinical Trials
Some currently ongoing or unpublished trials that might influence this review are listed in Table 6.

Table 6. Summary of Key Trials

References 

1. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. Jul 2017; 15(3): 334-365. PMID 28736337
2. Farrand KF, Fridman M, Stillman IÖ, et al. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol. Oct 2017; 182: 90-98. PMID 28705660
3. Blepharitis. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. San Francisco, CA: American Academy of Ophthalmology; 2018.
4. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. Mar 30 2011; 52(4): 1922-9. PMID 21450913
5. Blackie CA, Korb DR, Knop E, et al. Nonobvious obstructive meibomian gland dysfunction. Cornea. Dec 2010; 29(12): 1333-45. PMID 20847669
6. Dry Eye Syndrome. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. San Francisco, CA: American Academy of Ophthalmology; 2018.
7. Miller KL, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. Jan 2010; 128(1): 94-101. PMID 20065224
8. Ngo W, Situ P, Keir N, et al. Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire. Cornea. Sep 2013; 32(9): 1204-10. PMID 23846405
9. Tao JP, Shen JF, Aakalu VK, et al. Thermal Pulsation in the Management of Meibomian Gland Dysfunction and Dry Eye: A Report by the American Academy of Ophthalmology. Ophthalmology. Dec 2023; 130(12): 1336-1341. PMID 37642619
10. Lane SS, DuBiner HB, Epstein RJ, et al. A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea. Apr 2012; 31(4): 396-404. PMID 22222996
11. Finis D, Hayajneh J, König C, et al. Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial. Ocul Surf. Apr 2014; 12(2): 146-54. PMID 24725326
12. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016; 10: 1385-96. PMID 27555745
13. Tauber J. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction. Cornea. Apr 2020; 39(4): 403-407. PMID 31895884
14. Blackie CA, Coleman CA, Nichols KK, et al. A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day. Clin Ophthalmol. 2018; 12: 169-183. PMID 29398904
15. Kasetsuwan N, Suwajanakorn D, Tantipat C, et al. The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial. Clin Ophthalmol. 2020; 14: 2891-2902. PMID 33061275
16. Park J, Yoo YS, Shin K, et al. Effects of Lipiflow Treatment Prior to Cataract Surgery: A Prospective, Randomized, Controlled Study. Am J Ophthalmol. Oct 2021; 230: 264-275. PMID 33992615
17. Mencucci R, Mercuri S, Cennamo M, et al. Efficacy of vector thermal pulsation treatment in reducing postcataract surgery dry eye disease in patients affected by meibomian gland dysfunction. J Cataract Refract Surg. Apr 01 2023; 49(4): 423-429. PMID 36729441
18. Matossian C, Chang DH, Whitman J, et al. Preoperative Treatment of Meibomian Gland Dysfunction with a Vectored Thermal Pulsation System Prior to Extended Depth of Focus IOL Implantation. Ophthalmol Ther. Oct 2023; 12(5): 2427-2439. PMID 37318707
19. Meng Z, Chu X, Zhang C, et al. Efficacy and Safety evaluation of a single thermal pulsation system treatment (Lipiflow ® ) on meibomian gland dysfunction: a randomized controlled clinical trial. Int Ophthalmol. Apr 2023; 43(4): 1175-1184. PMID 36112256
20. Greiner JV. Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Exp Ophthalmol. Aug 2013; 41(6): 524-30. PMID 23145471
21. Finis D, König C, Hayajneh J, et al. Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy. Cornea. Dec 2014; 33(12): 1265-70. PMID 25321941
22. Greiner JV. Long-Term (3 Year) Effects of a Single Thermal Pulsation System Treatment on Meibomian Gland Function and Dry Eye Symptoms. Eye Contact Lens. Mar 2016; 42(2): 99-107. PMID 26222095
23. Hura AS, Epitropoulos AT, Czyz CN, et al. Visible Meibomian Gland Structure Increases After Vectored Thermal Pulsation Treatment in Dry Eye Disease Patients with Meibomian Gland Dysfunction. Clin Ophthalmol. 2020; 14: 4287-4296. PMID 33324034

Coding Section

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross Blue Shield Association technology assessment program (TEC) and other nonaffiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

"Current Procedural Terminology © American Medical Association. All Rights Reserved" 

History From 2024 Forward     

08/28/2024 Annual review, no change to policy intent. Updating regulatory status, rationale, and references

01012024  NEW POLICY